QueenslandXRay

PET/CT
MEDICARE ELIGIBILITY FOR SPECIALISTS

These items apply to patients referred by a specialist or consultant physician.

Breast—staging	Whole body FDG PET study, performed for the staging of locally advanced (Stage III) breast cancer in a patient considered potentially suitable for active therapy.
Breast—evaluation	Whole body FDG PET study, performed for the evaluation of suspected metastatic or suspected locally or regionally recurrent breast carcinoma in a patient considered suitable for active therapy.
Neuroendocrine Tumour Imaging	Whole body 68Ga-DOTATATE study if a gastro-entero-pancreatic neuroendocrine tumour is suspected of the basis of biochemical evidence with negative or equivocal conventional imaging or both a surgically amenable gastro-entero-pancreatic neuroendocrine tumour has been identified on the basis of conventional techniques and the study is for excluding additional disease sites.
Lung—Solitary Pulmonary Nodule	Whole body FDG PET study, performed for the evaluation of a solitary pulmonary nodule where the lesion is considered unsuitable for transthoracic fine needle aspiration biopsy, or for which an attempt at pathological characterisation has failed.
NSCLC	Whole body FDG PET study, performed for the staging of proven non-small cell lung cancer, where curative surgery or radiotherapy is planned.
Brain	FDG PET study of the brain for evaluation of suspected residual or recurrent malignant brain tumour based on anatomical imaging findings, after definitive therapy (or during ongoing chemotherapy) inpatients who are considered suitable for further active therapy.
Colorectal	Whole body FDG PET study, following initial therapy, for the evaluation of suspected residual, metastatic or recurrent colorectal carcinoma in patients considered suitable for active therapy.
Melanoma	Whole body FDG PET study, following initial therapy, performed for the evaluation of suspected metastatic or recurrent malignant melanoma in patients considered suitable for active therapy.
Epilepsy	FDG PET study of the brain, performed for the evaluation for refractory epilepsy which is being evaluated for surgery.
Ovarian	Whole body FDG PET study, following initial therapy, performed for the evaluation of suspected residual, metastatic or recurrent ovarian carcinoma in patients considered suitable for active therapy.
Uterine/Cervix	Whole body FDG PET study, for the further staging of patients with confirmed local recurrence of carcinoma of the uterine cervix considered suitable for salvage pelvic chemoradiotherapy or pelvic exenteration with curative intent.
Oesophageal/GEJ	Whole body FDG PET study, performed for the staging of proven oesophageal or GEJ carcinoma, in patients considered suitable for active therapy.

For more information on billing and locations,
visit our online Billing Guide **qldxray.com.au/billingguide**

QueenslandXRay

Head/Neck	Whole body FDG PET study performed for the staging of biopsy-proven newly diagnosed or recurrent head and neck cancer.
Head/Neck (Residual)	Whole body FDG PET study performed for the evaluation of patients with suspected residual head and neck cancer after definitive treatment, and who are suitable for active therapy.
Metastatic SCC—unknown primary	Whole body FDG PET study performed for the evaluation of metastatic squamous cell carcinoma of unknown primary site involving cervical nodes.
NHL—initial staging	Whole body FDG PET study performed for the initial staging of indolent non-Hodgkin's lymphoma where clinical, pathological and imaging findings indicate that the stage is I or IIA and the proposed management is definitive radiotherapy with curative intent.
Lymphoma—initial staging	Whole body FDG PET study for the initial staging of newly diagnosed or previously untreated Hodgkin's or non-Hodgkin's lymphoma (excluding indolent non-Hodgkin's lymphoma).
Lymphoma Therapy Response	Whole body FDG PET study to assess response to first line therapy either during treatment or within three months of completing definitive first line treatment for Hodgkin's or non-Hodgkin's lymphoma (excluding indolent non-Hodgkin's lymphoma).
Lymphoma—restaging	Whole body FDG PET study for restaging following confirmation of recurrence of Hodgkin's or non-Hodgkin's lymphoma (excluding indolent non-Hodgkin's lymphoma).
Lymphoma—post chemotherapy	Whole body FDG PET study to assess response to second-line chemotherapy when stem cell transplantation is being considered, for Hodgkin's or non-Hodgkin's lymphoma (excluding indolent non-Hodgkin's lymphoma).
Bone/Soft Tissue Sarcoma	Whole body FDG PET study for initial staging of patients with biopsy-proven bone or soft tissue sarcoma (excluding gastrointestinal stromal tumour) considered by conventional staging to be potentially curable.
Residual/Recurrent Sarcoma	Whole body FDG PET study for initial staging of patients with suspected residual or recurrent sarcoma (excluding gastrointestinal stromal tumour) after the initial course of definitive therapy to determine suitability for subsequent therapy with curative intent.
Alzheimer's disease	FDG PET study of the brain, performed for the diagnosis of Alzheimer's disease if clinical evaluation of the patient by a specialist is equivocal.
Prostate—Initial Staging	PSMA PET for intermediate to high-risk prostate adenocarcinoma, that has previously been untreated, and is considered suitable for locoregional therapy with curative intent.
Prostate—Restaging	PSMA PET for intermediate to high-risk prostate adenocarcinoma following locoregional therapy, and is considered suitable for further locoregional therapy.
Rare or uncommon cancers—Initial Staging	Whole body FDG PET study for the initial staging of eligible cancer types for a patient who is considered suitable for active therapy.